A new clinical trial founds Lynparza (olaparib), the MSD and AstraZeneca PARP inhibitor, to slow or stop tumor development in men affected with advanced prostate cancer.

Lynparza was found to be effective in over 80% of men with prostate cancer whose tumours had mutations in the BRCA genes.

The successful results raise the prospect that it could become the first ever gene-targeted drug to be approved for prostate cancer.

Men with BRCA transformations reacted best to the treatment, with over 80% reacting and 40% staying free of sickness movement for over a year. Furthermore, over portion of patients conveying PALB2 changes reacted to the medication, just as 37% of those with ATM transformations. Some 20% of patients with other DNA fix quality adjustments additionally reacted to Lynparza.

Men with advanced versions of the disease who had already received chemotherapy lived for more than 13 months on average when treated with Lynparza – and nearly 18 months among those with BRCA mutations.

On the discovery, the next step is to “work out how to combine olaparib with other drugs to keep cancer at bay for much longer’” explained Professor Paul Workman, chief executive at The Institute of Cancer Research.

He continued, “That’s the kind of research we will be carrying out in our new Centre for Cancer Drug Discovery, which aims to create innovative new treatments designed to overcome cancer evolution and drug resistance.”

Advanced prostate cancer can cause symptoms, such as fatigue, bone pain, and problems urinating.

For more information and fast delivery of the life-saving, latest FDA approved oncology drugs, please contact us at info@elixi-int.com

We are a Swiss pharmaceutical wholesaler, specialised in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.